VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
Trial details
- Registry ID
- NCT04842747
- Drugs studied
- VERU-111
TrialRedline tracks 6 clinical trials sponsored by Veru Inc.: 4 Phase 3, 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on StudyNCT04842747 | VERU-111 | Completed | 2022-07-06Actual |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943 | Enobosarm, Exemestane | Terminated | 2024-01-09Actual |
| Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast CancerNCT05065411 | Enobosarm & Abemaciclib Combo, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant | Terminated | 2023-10-19Actual |
| Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentNCT04844749 | Enzalutamide, Abiraterone, VERU-111 | Terminated | 2023-05-04Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight LossNCT07446998 | Enobosarm, Semaglutide (Wegovy) weekly injection | Active not recruiting | 2027-10Estimated |
| Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtNCT06282458 | Enobosarm, Semaglutide | Completed | 2025-04-11Actual |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: 200 participants (planned). After: 239 participants (actual).
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.